Microbiome therapeutic offers durable protection against C. difficile recurrence
May 28, 2021
“The hope would be that one or more ... would probably replace the vast majority of FMT [procedures] that we do clinically,”said Dr. Sahil Khanna.
Fecal microbiota transplantation impacts microRNAs implicated in recurrent C. difficile
May 4, 2021
“The findings from this study are extremely exciting and promising for the creation of novel therapeutics for patients with C. difficile.”
FMT cuts risk of bloodstream infections in patients with recurrent CDI
April 29, 2021
In patients with recurrent Clostridioides difficile infections (CDI), does fecal microbiota transplantation (FMT) decrease the risk of bloodstream infection (BSI) and related complications including hospital length of stay and death?
Emergent ERCP in acute cholangitis linked with better outcomes
March 22, 2021
Are outcomes better for patients with acute cholangitis (AC) if endoscopic retrograde cholangiopancreatography (ERCP) is done emergently (within 48 hours) versus urgently (more than 48 hours)?
COVID-19 may alter gut microbiota
January 29, 2021
Changes in gut microorganisms may contribute to severe disease and long-term symptoms after the virus clears.
Anticoagulation and antiplatelet therapy after GI bleed cut mortality, ischemic events
January 28, 2021
In patients who present with a gastrointestinal bleed (GIB) while on an anticoagulants (AC) or antiplatelets (AP), what are the risks and benefits to resuming these medications?
Updated USPSTF HBV screening recommendation may be a ‘lost opportunity’
January 12, 2021
The recommendation defines risk groups more narrowly than the CDC, AASLD, and some research suggests risk-based screening is ineffective for chronic conditions.
Anorexia and diarrhea top list of GI symptoms in COVID-19 patients
December 30, 2020
Increased ALT levels were the most common sign of abnormal liver function in adults with severe COVID-19.
COVID-19 vaccines: Safe for immunocompromised patients?
December 17, 2020
Data are limited thus far, and the safety and efficacy of the COVID-19 vaccines in immunocompromised patients remain unknown.
C. difficile control could require integrated approach
December 9, 2020
Australian researchers call for a One Health approach to limit spread.